Leo Pharma strongly criticizes Danish Medicines Council

A letter from Leo Pharma to the agency reveals that the pharmaceutical company is not satisfied with the Danish Medicines Council's assessment of eczema treatment Adtralza.

Photo: Leo Pharma / PR

Once again, the Danish Medicines Council has come under fire. According to Leo Pharma, the council has used the wrong methods to evaluate its eczema treatment Adtralza, affecting several assessment criteria.

This news was reported by Dagens Pharma, which has seen a letter Leo Pharma Nordic sent to the Danish Medicines Council.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs